Aspirin
Research News and Information

Monday, November 23, 2009

Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials.

4 Nov 2009 OBJECTIVE: To evaluate the benefits and harms of low dose aspirin in people with diabetes and no cardiovascular disease. DESIGN: Meta-analysis of randomised controlled trials. DATA SOURCES: Medline (1966-November 2008), the Cochrane central register ... Read more...

Genetic effect of CysLTR2 polymorphisms on its mRNA synthesis and stabilization.

18 Oct 2009 BACKGROUND: We previously demonstrated that single nucleotide polymorphism (SNP) and haplotypes were associated with aspirin hypersensitivity in asthmatics. We investigated the genetic effects of the SNPs and haplotypes on the expression of the ... Read more...

Clinical benefit of early reperfusion therapy in patients with ST-elevation myocardial infarction usually excluded from randomized clinical trials (results from the Maximal Individual Therapy in Acute Myocardial Infarction Plus [MITRA Plus] registry).

13 Oct 2009 Randomized clinical trials (RCTs) usually enroll selected patient populations that may not be representative for patients seen in everyday practice. Therefore, concerns have been raised regarding their external validity. For the present study we ... Read more...

Latest indexed articles for 'Aspirin'

These are the very latest articles for this heading:

• Aspirin for primary prevention of vascular disease in people with diabetes. 4 Nov 2009
• Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. 4 Nov 2009
• Anticoagulants for patients with prosthetic heart valves. 29 Oct 2009
• Responses to USPSTF guideline on aspirin for prevention of cardiovascular disease. 18 Oct 2009
• Responses to USPSTF guideline on aspirin for prevention of cardiovascular disease. 18 Oct 2009
• Genetic effect of CysLTR2 polymorphisms on its mRNA synthesis and stabilization. 18 Oct 2009
• Clinical benefit of early reperfusion therapy in patients with ST-elevation myocardial infarction usually excluded from randomized clinical trials (results from the Maximal Individual Therapy in Acute Myocardial Infarction Plus [MITRA Plus] registry). 13 Oct 2009
• Bleeding increases the risk of ischemic events in patients with peripheral arterial disease. 3 Oct 2009
• Time-dependent effects of low-dose aspirin on plasma renin activity, aldosterone, cortisol, and catecholamines. 3 Oct 2009
• Antiplatelet agents used for early intervention in acute coronary syndrome: myocardial salvage versus bleeding complications. 29 Sep 2009
• Randomized controlled trial of aspirin and clopidogrel versus aspirin and placebo on markers of smooth muscle proliferation before and after peripheral angioplasty. 29 Sep 2009
• Impact of coronary computed tomographic angiography findings on the medical treatment and control of coronary artery disease and its risk factors. 29 Sep 2009
• Tumor markers and rectal cancer: support for an inflammation-related pathway. 29 Sep 2009
• Induced cardiovascular procedural costs and resource consumption patterns after coronary artery calcium screening: results from the EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) study. 27 Sep 2009
• Clopidogrel plus aspirin in atrial fibrillation. 22 Sep 2009
• Clopidogrel plus aspirin in atrial fibrillation. 22 Sep 2009
• Clopidogrel plus aspirin in atrial fibrillation. 22 Sep 2009
• Clopidogrel plus aspirin in atrial fibrillation. 22 Sep 2009
• Clopidogrel plus aspirin in atrial fibrillation. 22 Sep 2009
• Clopidogrel plus aspirin in atrial fibrillation. 22 Sep 2009

See a longer list of these articles.

Technical information about 'Aspirin'

Definition: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)

Chemical name: Benzoic acid, 2-(acetyloxy)-

Registry Number: 50-78-2

Descriptor UI: D001241

Alternative terms: Aspirin; Acetylsalicylic Acid; Acid, Acetylsalicylic; 2-(Acetyloxy)benzoic Acid; Acylpyrin; Aloxiprimum; Colfarit; Dispril; Easprin; Ecotrin; Endosprin; Magnecyl; Micristin; Polopirin; Polopiryna; Solprin; Solupsan; Zorprin; Acetysal;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Anti-Inflammatory Agents, Non-Steroidal; Fibrinolytic Agents; Platelet Aggregation Inhibitors; Cyclooxygenase Inhibitors;

Tree Number: D02.241.223.100.380.800.075; D02.241.511.390.700.075; D02.755.410.700.075;

History Note: 65; was ACETYLSALICYLIC ACID 1963-64